Real-World Evidence For Accelerated Approval: NASEM Is A Tough Crowd
Executive Summary
Biopharma companies continue to hold out hopes that Real-World Evidence can help expand use of the US FDA accelerated approval pathway by making confirmatory studies more viable. A recent National Academies of Science, Engineering and Medicine workshop suggests there is a long way to go in building a broader consensus behind the approach.